29.86
price up icon1.05%   0.31
pre-market  Pre-market:  30.24   0.38   +1.27%
loading
Tg Therapeutics Inc stock is traded at $29.86, with a volume of 2.08M. It is up +1.05% in the last 24 hours and down -7.27% over the past month.
See More
Previous Close:
$29.55
Open:
$29.9
24h Volume:
2.08M
Relative Volume:
0.72
Market Cap:
$4.60B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-271.45
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
+0.40%
1M Performance:
-7.27%
6M Performance:
+42.19%
1Y Performance:
+98.14%
1-Day Range:
Value
$29.51
$30.33
1-Week Range:
Value
$28.62
$31.02
52-Week Range:
Value
$12.84
$36.84

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name
Name
Tg Therapeutics Inc
Name
Phone
(212) 554-4484
Name
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Name
Employee
0
Name
Twitter
@TGTherapeutics
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
TGTX's Discussions on Twitter

Compare TGTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TGTX
Tg Therapeutics Inc
29.86 4.60B 264.79M -14.36M -28.11M -0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-29-24 Initiated TD Cowen Buy
Aug-02-23 Upgrade Goldman Sell → Neutral
Jun-26-23 Resumed Jefferies Buy
May-20-22 Initiated BofA Securities Underperform
Feb-23-22 Reiterated B. Riley Securities Buy
Nov-15-21 Downgrade Goldman Neutral → Sell
Apr-20-21 Initiated Goldman Neutral
Apr-19-21 Reiterated H.C. Wainwright Buy
Sep-01-20 Initiated JP Morgan Overweight
Aug-11-20 Reiterated H.C. Wainwright Buy
Jun-05-20 Initiated Evercore ISI Outperform
Jan-17-20 Reiterated H.C. Wainwright Buy
Nov-27-19 Resumed B. Riley FBR Buy
Feb-06-19 Resumed Jefferies Buy
Sep-25-18 Downgrade Raymond James Strong Buy → Outperform
Mar-09-18 Reiterated B. Riley FBR, Inc. Buy
Dec-01-17 Resumed B. Riley FBR, Inc. Buy
Nov-14-17 Resumed H.C. Wainwright Buy
Apr-25-17 Initiated Jefferies Buy
Mar-06-17 Reiterated FBR & Co. Outperform
Oct-06-16 Resumed Brean Capital Buy
May-27-16 Initiated SunTrust Buy
Dec-01-15 Initiated FBR Capital Outperform
Sep-09-15 Initiated Raymond James Strong Buy
Aug-12-15 Resumed H.C. Wainwright Buy
Jun-19-15 Reiterated Brean Capital Buy
Dec-11-14 Reiterated ROTH Capital Buy
Dec-10-14 Reiterated ROTH Capital Buy
View All

Tg Therapeutics Inc Stock (TGTX) Latest News

pulisher
03:25 AM

Assenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

03:25 AM
pulisher
Jan 21, 2025

TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha

Jan 21, 2025
pulisher
Jan 20, 2025

12 Hot Stocks to Buy According to Analysts - Insider Monkey

Jan 20, 2025
pulisher
Jan 20, 2025

Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey

Jan 20, 2025
pulisher
Jan 18, 2025

TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

(TGTX) Trading Signals - Stock Traders Daily

Jan 18, 2025
pulisher
Jan 17, 2025

Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha

Jan 16, 2025
pulisher
Jan 16, 2025

TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN

Jan 15, 2025
pulisher
Jan 15, 2025

Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance

Jan 15, 2025
pulisher
Jan 15, 2025

Have Insiders Sold TG Therapeutics Shares Recently? - Simply Wall St

Jan 15, 2025
pulisher
Jan 15, 2025

Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts - Benzinga

Jan 15, 2025
pulisher
Jan 14, 2025

10 Firms Post Impressive Gains on Tuesday - Insider Monkey

Jan 14, 2025
pulisher
Jan 14, 2025

Why TGTX Stock Is Rallying Today - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics Reports Strong Revenue and Future Goals - TipRanks

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug - MarketWatch

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics Provides Preliminary Fourth Quarter and - GlobeNewswire

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics (NASDAQ:TGTX) Shares Gap UpHere's Why - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics projects $540 million in 2025 revenue By Investing.com - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

What's Going On With TG Therapeutics Stock Tuesday? - Benzinga

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics says 2024 Briumvi sales topped expectations - MSN

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics stock rises on strong Q4 and full-year revenue - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics stock rises on strong Q4 and full-year revenue By Investing.com - Investing.com South Africa

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics stock gains on Briumvi sales (TGTX:NASDAQ) - Seeking Alpha

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics projects $540 million in 2025 revenue - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

TG Therapeutics' BRIUMVI Hits $310M Revenue in 2024, Projects 75% Growth for 2025 - StockTitan

Jan 14, 2025
pulisher
Jan 14, 2025

Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $40.67 - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst (NASDAQ:TGTX) - Seeking Alpha

Jan 13, 2025
pulisher
Jan 11, 2025

JPMorgan Chase & Co. Buys 270,286 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat

Jan 11, 2025
pulisher
Jan 10, 2025

Should You Invest in TG Therapeutics (TGTX)? - Insider Monkey

Jan 10, 2025
pulisher
Jan 09, 2025

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 09, 2025
pulisher
Jan 09, 2025

TG Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 09, 2025
pulisher
Jan 09, 2025

Vanguard Group Inc's Strategic Acquisition of TG Therapeutics In - GuruFocus.com

Jan 09, 2025
pulisher
Jan 08, 2025

Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail

Jan 08, 2025
pulisher
Jan 08, 2025

TG Therapeutics CFO Sean Power sells $629,382 in common stock - Investing.com India

Jan 08, 2025
pulisher
Jan 08, 2025

TG Therapeutics price target raised to $10 from $9 at BofA - Yahoo Finance

Jan 08, 2025
pulisher
Jan 07, 2025

TG Therapeutics (NASDAQ:TGTX) Rating Increased to Hold at StockNews.com - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power Sells 10,021 Shares - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells 11,337 Shares of Stock - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

TG Therapeutics CFO Sean Power sells $629,382 in common stock By Investing.com - Investing.com Nigeria

Jan 07, 2025
pulisher
Jan 07, 2025

How To Trade (TGTX) - Stock Traders Daily

Jan 07, 2025
pulisher
Jan 07, 2025

TG Therapeutics (NASDAQ:TGTX) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Jan 07, 2025
pulisher
Jan 06, 2025

TG Therapeutics (NASDAQ:TGTX) Shares Down 2.9%Time to Sell? - MarketBeat

Jan 06, 2025

Tg Therapeutics Inc Stock (TGTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
Cap:     |  Volume (24h):